Eligibility

Approval Status

One product with limited approval

Two products in phase 3

Year of First Approval

2023

Approved Population

Adults (12+) with inhibitors

Administration

Administration & Dosing

24 hr or 1x/MONTH

Location

Home or Treatment Center

Yearly Follow-up Schedule

2

Every 6 months and as needed

Efficacy

Median Annual Bleed Rate

<2.5

median for all bleeds, regardless of whether the bleed was treated, spontaneous, or traumatic

% With Zero Bleeds

not reported

Factor Level

(approximate representations of factor half-life)



Factor levels will not change, but the effect is similar to having mild hemophilia

Safety Considerations

Adverse Reactions

The most common adverse reactions are injection site reactions, joint pain, upper respiratory tract infections, headache, and fever.

Potential Safety Risks

Hypersensitivity Reactions

<3%

Inhibitors

–

Thrombotic Events

<1%

Occurred in patients taking additional clotting agents

Elevated Liver Enzymes

–

Psychosocial Burden

Seeking a Hemophilia Free Mind



Modified from Krumb & Hermans; "Living with a "hemophilia-free mind" - the new ambition of hemophilia care?"; 2021

Data was sourced from the FDA, EMA, and Health Canada prescribing information and applicable and published Phase 3 clinical studies.
Last Update: March 2024.